Abstract 216P
Background
Wilms tumor (WT) is a rare kidney cancer, but it is the most common malignant tumor of the kidneys of children. Although radical nephroectomy has been viewed as the gold standard surgery in Wilms tumor management for many years, partial nephrectomy has gained a lot of attention recently. So we conducted this study to compare the long term overall survival between those two different surgical techniques.
Methods
Using SEER database, we extracted the data of 636 patients with WT from 2000 to 2006. There were 55 (8.6%) patients underwent partial nephrectomy, while 581 (91.4%) of them underwent radical nephrectomy. Patients’ demographics were assessed.
Results
Our study showed that there is NO significant difference in Long-Term overall survival between partial nephrectomy and radical nephrectomy, where overall 10-year relative survival rates were 92.6% and 88.1%, respectively (p value =0.240). Subgroup analysis revealed NO significant difference in overall survival Except in patients with different age groups as seen in the table (p value <0.0001) but this could have been caused by the fact that few patients were recorded.
Table: 216P
Variables | Survival of Patients | p value | |
---|---|---|---|
Partial nephroectomy | Radical nephroectomy | ||
Sex Male Female | 96 % 89.7 % | 87.9 % 88.3 % | 0.821 |
Age 0- 9 10-19 20-39 40-59 60-79 | 91.5% 100%** 100%** 100%** 100%** | 89.9% 71.8% 36.4% 100% 66.7% | <0.0001*** |
Race White | 91% 100% _* % _* % | 88.8% 86.1% 88.9% 83.3% | 0.574 |
Black American Indian/Alaska Asian/pacific Islander | |||
Laterality Right left Bilateral | 89.9% 92.9% 95% | 90.1% 85.8% 92% | 0.175 |
Highly significant P-value ≤ 0.001.
**few no. of cases _.
*no recorded patients.
Conclusions
There is NO significant difference in overall 10-year survival between partial nephrectomy and radical nephrectomy. So, we recommend the application of partial nephrectomy in the appropriate patients to preserve as much kidney tissue and function as possible especially in bilateral WT. Further studies should be conducted on larger number of patients and they should study the efficacy of chemotherapy in patients undergoing partial nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mira Mohamed Mostafa.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract